Skip to content
Screener

Nuvation Bio NUVB Current Debt

Discontinued — last reported Q2 '26

Current Debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.03B-78.2%
Pfizer logo
PfizerPFE
$3.86B+3.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$22.5M—
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$53K—
Eli Lilly logo
Eli LillyLLY
$7.05B+23.2%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.15B+168%
Enterprise value$1.9B+211%
P/S12.6×-43.1×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity0×-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:ShortTermBorrowings.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646

FAQ

What is Nuvation Bio's current debt?
Nuvation Bio (NUVB) reported current debt of $5.89M in Q2 2026.
How has Nuvation Bio's current debt changed year-over-year?
Nuvation Bio's current debt increased by 5.6% year-over-year, from $5.58M to $5.89M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Ask your AI about Nuvation Bio's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude